Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $205.8 million versus the consensus estimate of $208.37 million.

Acadia is reiterating all of its 2024 guidance provided on February 27, 2024:

DAYBUE net product sales guidance in the range of $370 to $420 million.
NUPLAZID net product sales guidance in the range of $560 to $590 million.
R&D expense in the range of $305 to $325 million.
SG&A expense in the range of $455 to $480 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
• Worthington Industries (WOR) Misses Q4 EPS by 9c